Abstract
Background Faster nicotine metabolism, defined as the nicotine metabolite ratio (NMR), is known to associate with heavier smoking and challenges in smoking cessation. However, the broader health implications of genetically determined nicotine metabolism are not well characterized.
Methods We performed a hypothesis-free phenome-wide association study (PheWAS) of over 21,000 outcome variables from UK Biobank (UKB) to explore how the NMR (measured as the 3-hydroxycotinine-to-cotinine ratio) associates with the phenome. As the exposure variable, we used a genetic score for faster nicotine metabolism based on 10 putative causal genetic variants, explaining 33.8 % of the variance in the NMR. We analysed ever and never smokers separately to assess whether a causal pathway through nicotine metabolism is plausible.
Results A total of 57 outcome variables reached phenome-wide significance at a false discovery rate of 5 %. We observed expected associations with several phenotypes related to smoking and nicotine, but could not replicate prior findings on cessation. Importantly, we found novel associations between genetically determined faster nicotine metabolism and adverse health outcomes, including unfavourable liver enzyme and lipid values, as well as increased caffeine consumption. These associations did not appear to differ between ever and never smokers, suggesting the corresponding pathways may not involve nicotine metabolism. No favourable health outcomes were linked to genetically determined faster nicotine metabolism.
Conclusions Our findings support a possibility that a future smoking cessation therapy converting fast metabolizers of nicotine to slower ones could work without adverse side effects and potentially even provide other health-related benefits.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study has been funded by the Doctoral Program in Population Health and the Doctoral School in Health Sciences from the University of Helsinki, as well as Yrjo Jahnsson Foundation to JB, by the Academy of Finland (grants 338507, 336825 and 352795) and Sigrid Juselius Foundation to MP and JK, and by the Academy of Finland Center of Excellence in Complex Disease Genetics (grants 336823, 352792), and the Finnish Foundation for Cardiovascular Research to JK. VS was supported by the Juho Vainio Foundation. The FINRISK surveys have been mainly funded from budgetary funds of THL. Important additional funding has been obtained from the Academy of Finland and from several domestic foundations. The YFS has been financially supported by the following sources: Academy of Finland (grant numbers 356405, 322098, 286284, 134309 (Eye), 126925, 121584, 124282, 255381, 256474, 283115, 319060, 320297, 314389, 338395, 330809, and 104821, 129378 (Salve), 117797 (Gendi), and 141071 (Skidi)); the Social Insurance Institution of Finland; Competitive State Research Financing of the Expert Responsibility Area of Kuopio, Tampere and Turku University Hospitals (grant X51001); the Juho Vainio Foundation; the Paavo Nurmi Foundation; the Finnish Foundation for Cardiovascular Research; the Finnish Cultural Foundation; the Sigrid Juselius Foundation; the Tampere Tuberculosis Foundation; the Emil Aaltonen Foundation; the Yrjo Jahnsson Foundation; the Signe and Ane Gyllenberg Foundation; the Diabetes Research Foundation of Finnish Diabetes Association; EU Horizon 2020 (grant 755320 for TAXINOMISIS and grant 848146 for To Aition); the European Research Council (grant 742927 for MULTIEPIGEN project); the Tampere University Hospital Supporting Foundation, Finnish Society of Clinical Chemistry; the Cancer Foundation Finland; pBETTER4U_EU (Preventing obesity through Biologically and bEhaviorally Tailored inTERventions for you; project number: 101080117); and the Jane and Aatos Erkko Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
UKB was approved by the North West Multi-center Research Ethics Committee. The Coordinating Ethics Committee of the Helsinki and Uusimaa Hospital District approved the FINRISK surveys (decision number 229/E0/06 in 2007 and 162/13/03/00/11 in 2012). The University Hospital ethics committees in Turku and Tampere approved the YFS study. All participants provided written informed consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
More description on the GxE MR-pheWAS approach, sex and ancestry-specific analyses added, updated Supplemental files.
Data Availability
Access to the UK Biobank data can be applied at http://ukbiobank.ac.uk/register-apply/. To apply for access to the YFS data see: http://youngfinnsstudy.utu.fi/, and for FINRISK see: https://thl.fi/en/web/thl-biobank. All analyses were performed in R and bash. Scripts will be deposited on GitHub upon publication of the manuscript.